News

BioVie Presents Data for NE3107 at 2023 International Congress of Parkinson’s Disease and Movement Disorders

New preclinical data characterizing NE3107 mechanism of action featured in oral presentationPhamacokinetic data from Phase 2a study supports potential co-administration…

1 year ago

Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel…

1 year ago

Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023

STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed…

1 year ago

Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024

WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical…

1 year ago

Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium

ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions at WIO and received an…

1 year ago

Bionano Announces Second OEM Partner has Received China NMPA Approval for DNA Extraction and Labeling Products for IVD Use of OGM in Reproductive Health

Bionano original equipment manufacturing (OEM) partner A-smart MedTech (A-smart) obtained reagent class I registration and approval for DNA isolation and…

1 year ago

Atsena Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of ATSN-201 for the Treatment of X-linked Retinoschisis

The LIGHTHOUSE study evaluating the safety and tolerability of investigational gene therapy ATSN-201 is enrolling male patients ages 6-64 with…

1 year ago

Superluminal Medicines Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics

Financing led by RA Capital Management with participation from Insight Partners, NVIDIA, and Gaingels Superluminal combines deep biology and chemistry…

1 year ago

Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results

$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into 4Q 2026 Phase 1 clinical…

1 year ago

LEXEO Therapeutics Announces Strategic Investment from Sarepta Therapeutics to Support Development of LEXEO’s Cardiovascular Gene Therapies

Companies to explore collaboration opportunities within LEXEO’s preclinical cardiovascular pipelineNEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- LEXEO Therapeutics (LEXEO),…

1 year ago